Access and implementation barriers to SGLT2 inhibitor use for type 2 diabetes in Palestine: a cross-sectional health services survey of physicians
A cross-sectional survey of 121 Palestinian physicians reveals that while attitudes toward SGLT2 inhibitors are moderately favorable, their implementation for type 2 diabetes is significantly hindered by high costs, limited prescribing knowledge, and health-system barriers, necessitating combined educational and policy interventions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the landscape of modern medicine, type 2 diabetes is more than just a problem of high blood sugar; it is a condition that quietly strains the heart and the kidneys, often leading to serious complications years after a diagnosis. For decades, doctors focused primarily on lowering glucose levels, but a newer class of medicines has changed the conversation. These drugs, known as SGLT2 inhibitors, do more than just manage sugar; they have been shown to protect the heart and kidneys, offering a shield against the most dangerous consequences of the disease. Guidelines from medical experts around the world now suggest that for many patients, these protective medicines should be considered early in treatment. Yet, in many places, the promise of these drugs has not fully reached the patients who need them. The gap between what medical science recommends and what happens in a doctor's office is often filled with practical hurdles: questions about who qualifies for the treatment, concerns about side effects, and the very real issue of whether a patient can afford the prescription.
In the northern West Bank of Palestine, a team of researchers set out to understand why this gap exists. They were interested in the daily reality of doctors who treat diabetes in hospitals and community clinics across cities like Nablus, Jenin, and Tulkarm. The researchers wanted to know if these physicians knew how to use these new protective medicines, whether they felt confident prescribing them, and what stood in their way. They surveyed 121 doctors, asking them about their knowledge, their feelings toward the treatment, and the barriers they face in their specific healthcare environment. The goal was not to judge the doctors, but to map the terrain of their practice, identifying where the path to better care is blocked so that those blocks could be removed.
The survey revealed a story of mixed feelings and practical constraints. The doctors generally held a positive view of the new medicines. When asked if they felt comfortable prescribing them or if they understood which patients would benefit, the responses were moderately favorable. Many felt they had the training to make good choices, and a significant portion expressed confidence in their ability to select the right medication for the right person. However, this confidence did not match their actual knowledge of the specific rules for using these drugs. When tested on the details—such as exactly when to start the medicine, how to adjust it for patients with kidney issues, or what the specific safety limits are—the doctors' scores were surprisingly low. More than half of the participants fell into a category of low knowledge, and no single doctor answered every question correctly. It was as if the doctors knew the destination was important but were unsure of the exact map required to get there.
The most significant obstacle, however, was not a lack of confidence or even a lack of knowledge, but the simple, heavy weight of cost. When the doctors were asked what stopped them from prescribing these medicines, the most common answer was that the drugs were too expensive for their patients. Nearly three-quarters of the doctors agreed that cost was a major barrier. This financial hurdle was followed by the presence of other, cheaper diabetes medications that doctors were already familiar with, and a lack of specific knowledge about the new drug itself. The researchers found that while the doctors were willing to use these medicines, the system around them made it difficult. In a healthcare environment where resources are tight and patients often pay out of pocket, the price tag of a medicine can be a louder voice than the medical guidelines.
The study also looked at whether experience or job title made a difference. They found that doctors with more years of experience and those who specialized in endocrinology or were senior consultants tended to feel more confident and knew more about the drugs than their younger colleagues or general practitioners. However, the researchers were careful to note that these differences were observed in a small group and should be seen as clues for future study rather than final proof. The main takeaway remained consistent across all groups: the doctors wanted to help, but they were held back by a combination of uncertainty about the details and the economic reality of their patients.
Ultimately, the research suggests that simply telling doctors to use these new medicines is not enough. The findings point to a need for a two-part solution. First, doctors need clear, practical education that fills the gaps in their specific knowledge, helping them understand exactly how to use these drugs safely and effectively. Second, and perhaps more critically, the healthcare system needs to address the affordability of the medicines. If the cost remains a barrier, even the most knowledgeable and willing doctor will struggle to provide the best care. The study concludes that for these life-saving medicines to reach the patients who need them in Palestine, educational efforts must be paired with policies that clarify how patients can access and afford these treatments. The path forward requires fixing both the mind of the prescriber and the wallet of the patient.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.